07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

ME-143: Phase I data

An open-label, U.S. Phase I trial in 15 patients with refractory solid tumors showed that once-weekly 2.5, 5, 10 and 20 mg/kg doses of IV ME-143 were generally well tolerated with 1 serious infusion reaction...
07:00 , Jun 11, 2012 |  BioCentury  |  Finance

Aches for Achillion

Public investors in Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lopped $34 million off the HCV company's valuation last week based on two events: the departure of a senior executive and the distribution and sale of some shares...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Clinical News

ME-344: Phase I started

Marshall Edwards began an open-label, dose-escalation, U.S. Phase I trial to evaluate once-weekly 1.2, 2.5, 5, 10 and 20 mg/kg IV ME-344 for the first 3 weeks of a 28-day cycle in up to 24...
07:00 , May 21, 2012 |  BC Week In Review  |  Financial News

Marshall Edwards completes rights offering of units

Marshall Edwards Inc. (NASDAQ: MSHL), San Diego, Calif.   Business: Cancer   Date completed: 5/14/12   Type: Rights offering of units   Raised: $5.2 million   Units: 11.7 million   Price: $0.45 (unit)   Shares...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Clinical News

ME-344: Phase I start

Next month, Marshall Edwards will begin an open-label, dose-escalation Phase I trial to evaluate once-weekly 1.2, 2.5, 5, 10 and 20 mg/kg IV ME-344 in up to 24 patients. Marshall Edwards Inc. (NASDAQ:MSHL), San Diego,...
07:00 , Mar 26, 2012 |  BC Week In Review  |  Financial News

Marshall Edwards amends rights offering of units

Marshall Edwards Inc. (NASDAQ:MSHL), San Diego, Calif.   Business: Cancer   Date announced: 3/19/12   Type: Rights offering of units   To be raised: Up to $7.6 million   Shares: 17.1 million   Price: $0.45...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Financial News

Marshall Edwards proposes rights offering

are eligible to purchase one share for every share held. Marshall Edwards Inc. (NASDAQ: MSHL), San Diego, Calif.   Business: Cancer   Date announced: 2/21/12   Type: Rights offering   To be raised: Up to...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Financial News

Marshall Edwards completes private placement

Marshall Edwards Inc. (NASDAQ:MSHL), San Diego, Calif.   Business: Cancer   Date completed: 12/29/11   Type: Private placement   Raised: $2 million   Shares: 1.9 million   Price: $1.03   Shares after offering: 13.8 million...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Ausio, Marshall Edwards deal

Marshall Edwards granted Ausio exclusive, worldwide rights to develop and commercialize isoflavone metabolite equol for non-cancer indications. Marshall Edwards is eligible for royalties and a royalty-free license to undisclosed manufacturing-related IP from Ausio. Terms were...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Financial News

Marshall Edwards completes private placement

Marshall Edwards Inc. (NASDAQ: MSHL), San Diego, Calif.   Business: Cancer   Date completed: 9/28/11   Type: Private placement   Raised: $2 million   Shares: 1.3 million   Price: $1.50   Shares after offering: 11.5...